AGI Therapeutics Gets Financing

07.06.2004

Dublin - Irish AGI Therapeutics Ltd. in mid-May completed Euro9.5 million-first round financing. The development stage speciality pharmaceutical company will put the money from lead investor ACT Venture Capita and Seroba BioVentures, Delta Partners as well as Merlin Biomed Group into the development of six pipeline products and initiate Phase II clinical trials on four of its gastroenterology pro-ducts: AGI-001 for non-ulcer dyspepsia (NUD), AGI-003 for irritable bowel syndrome (IBS), AGI-004 for functional diarrhoea and AGI-010 for the prevention of nocturnal acid breakthrough (NAB) in gastroesophageal reflux disease (GERD). The company also announced to commence initial clinical testing of its AGI-006 pipeline product in patients with diabetic gastroparesis.

While on a trip to strengthen economic ties between Ireland and California, Ireland's minister for jobs, enterprise and innovation, Richard Bruton, revealed on 15 March that two Irish government organisations have provided...

Dublin – Irish drugmaker Shire plc has agreed to pay US-$100m in upfront for Ferrokin Biosciences Inc., a San Francisco-based specialist for iron chelation therapies. US-$225m could be added if certain milestones are achieved....

Abbott Laboratories is to spend a85m and expand its pharmaceutical manu­facturing facility in Sligo (Ireland), saying that would help the company to ensure its supply of compounds in bio­pharmaceutical areas like virology and...

Sligo - Abbott Laboratories is to spend €85m euros and expand its pharmaceutical manufacturing facility in Sligo, Ireland. It should help to ensure the supply of compounds in biopharmaceutical areas like virology and nephrology,...

Weston/Dublin - The focus for Tysabri, the MS drug jointly developed by Irish Elan and US-Biogen, has become a little more accurate. The US Food and Drug Administration (FDA) stated that the occurrence of antibodies against the...

Dublin/Cambridge – The University of Cambridge and Irish drugmaker Elan Pharmaceutical Inc. have joined forces in the battle against Alzheimer’s Disease. Together, the two will create the Cambridge-Elan Centre for Research...

Uppsala/Craigavon - Irish Almac trusts a Swedish platform to develop new cancer drug candidates. As Uppsala-based Beactica announced on Tuesday, its Sprint-technology will be used to identify fragment hits against a number of...

Dublin /New York – Irish Tibotec Pharmaceutical Ltd and Bristol-Myers Squibb (BMS) have entered into a clinical collaboration for the treatment of chronic hepatitis C infections with a combination of BMS’ NS5A replication complex...

Dublin/Cmbridge (UK) – The University of Cambridge and Irish drugmaker Elan Pharmaceutical have joined forces in the battle against Alzheimer’s Disease. Together, the two will create a new research centre dedicated to...

Athlone – Biopharma group Alkermes has established its new Irish corporate base following its merger with Elan Drug Tech­nologies. The a712m (US$960m) deal agreed back in May – which saw Alkermes acquire Elan’s Athlone-based drug...

Free newsletter!

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...